A large, multi-institution study led by a Brown University physician-scientist could have important implications for the development of new classes of cancer therapeutics.
The mechanistic target of rapamycin complex 1 (mTORC1) is recruited to the lysosome by Rag guanosine triphosphatases (GTPases) and regulates anabolic pathways in response to nutrients. We found that ...
Novartis has offloaded two midphase mTORC1 inhibitors to PureTech Health. The agreement will see PureTech create a subsidiary, resTORbio, to move the assets into a phase 2b trial in diseases linked to ...
The TSC Alliance Endowment Fund, a supporting organization of the TSC Alliance, has invested in Aeovian Pharmaceuticals as ...
The mammalian target of rapamycin (mTOR) protein, a member of the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family, has a central role in two growth-regulatory pathways that have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback